Imperial College London
Portrait Picture

ProfessorNicholaCooper

Faculty of Medicine, Department of Immunology and Inflammation

Professor of Immune Haematology
 
 
 
//

Contact

 

n.cooper

 
 
//

Assistant

 

Miss Mandy Sale +44 (0)20 3313 4017

 
//

Location

 

4S10CCommonwealth BuildingHammersmith Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Robbins:2023:10.1111/bcp.15618,
author = {Robbins, AJ and Che, Bakri NA and Toke-Bjolgerud, E and Edwards, A and Vikraman, A and Michalsky, C and Fossler, M and Lemm, N-M and Medhipour, S and Budd, W and Gravani, A and Hurley, L and Kapil, V and Jackson, A and Lonsdale, D and Latham, V and Laffan, M and Chapman, N and Cooper, N and Szydlo, R and Boyle, J and Pollock, KM and Owen, D},
doi = {10.1111/bcp.15618},
journal = {British Journal of Clinical Pharmacology},
pages = {1495--1501},
title = {The effect of TRV027 on coagulation in COVID 19: A pilot randomized, placebo-controlled controlled trial},
url = {http://dx.doi.org/10.1111/bcp.15618},
volume = {89},
year = {2023}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - COVID-19 causes significant thrombosis and coagulopathy, with elevated D-dimer a predictor of adverse outcome. The precise mechanism of this coagulopathy remains unclear, one hypothesis is that loss of Angiotensin Converting Enzyme 2 activity during viral endocytosis leads to pro-inflammatory angiotensin II accumulation, loss of angiotensin-1-7 and subsequent vascular endothelial activation. We undertook a double blind randomised, placebo controlled experimental medicine study to assess the effect of TRV027, a synthetic angiotensin-1-7 analogue on D-dimer in 30 patients admitted to hospital with COVID-19 (REC ref. 20/HRA/3414), Clinical Trial No. NCT04419610.The study showed a similar rate of adverse events in TRV027 and control groups. There was a numerical decrease in D-dimer in the TRV027 group and increase in D-dimer in the placebo group, however, this did not reach statistical significance (p=0.15). A Bayesian analysis demonstrated there was a 92% probability that this change represented a true drug effect.
AU  - Robbins,AJ
AU  - Che,Bakri NA
AU  - Toke-Bjolgerud,E
AU  - Edwards,A
AU  - Vikraman,A
AU  - Michalsky,C
AU  - Fossler,M
AU  - Lemm,N-M
AU  - Medhipour,S
AU  - Budd,W
AU  - Gravani,A
AU  - Hurley,L
AU  - Kapil,V
AU  - Jackson,A
AU  - Lonsdale,D
AU  - Latham,V
AU  - Laffan,M
AU  - Chapman,N
AU  - Cooper,N
AU  - Szydlo,R
AU  - Boyle,J
AU  - Pollock,KM
AU  - Owen,D
DO  - 10.1111/bcp.15618
EP  - 1501
PY  - 2023///
SN  - 0306-5251
SP  - 1495
TI  - The effect of TRV027 on coagulation in COVID 19: A pilot randomized, placebo-controlled controlled trial
T2  - British Journal of Clinical Pharmacology
UR  - http://dx.doi.org/10.1111/bcp.15618
UR  - https://bpspubs.onlinelibrary.wiley.com/doi/10.1111/bcp.15618
UR  - http://hdl.handle.net/10044/1/100559
VL  - 89
ER  -
Download